PCA
ALLO icon

Pallas Capital Advisors’s Allogene Therapeutics ALLO Stock Holding History

Pallas Capital Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64K Buy
26,238
+13,223
+102% +$26.5K ﹤0.01% 820
2025
Q4 		$17.8K Buy
+13,015
New +$17.2K ﹤0.01% 881

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pallas Capital Advisors's ALLO Position: Q1 2026 in Review

Pallas Capital Advisors increased its Allogene Therapeutics (ALLO) stake by 102% in Q1 2026, buying an estimated $26.5K and bringing the position to 26,238 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #820.

Pallas Capital Advisors first reported a position in ALLO in Q4 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Pallas Capital Advisors held 26,238 shares of Allogene Therapeutics worth $64K as of Q1 2026.
  • Pallas Capital Advisors bought 13,223 Allogene Therapeutics shares in Q1 2026, an estimated $26.5K.
  • Allogene Therapeutics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #820 holding.
  • Pallas Capital Advisors first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.